MindAffect

MindAffect sits at the intersection of medical devices, digital health, neuroscience and AI, with a focus on brain-computer interfaces for communication and sensory diagnostics. Its product set points to a practical clinical emphasis: Sofi® targets objective hearing assessment, KinderCap combines hearing and vision testing for preschool children, and a separate prototype addresses visual acuity. The ConsciousMinds BCI Speller extends the underlying brain-response approach toward communication support. These use cases distinguish the company’s stated focus from general-purpose software by pairing signal analysis with dedicated assessment or communication hardware. MindAffect’s scale also appears small: its employee range is listed as one to ten, with two current leadership positions identified. Its competitive position is therefore best characterized by a specialized medical BCI application portfolio, rather than demonstrated scale or broad market penetration. The company’s differentiation rests on applying brain-response measurements to patients who may struggle with conventional, communication-dependent tests.

Founded in 2017, MindAffect’s funding history shows an early-stage development path with three recorded rounds. It received a pre-seed investment in May 2017, with no amount specified, followed by a €1 million seed round in May 2018, equivalent to $1,193,125. The clearest financing inflection came on Apr 29, 2024, when it raised €1.1 million ($1,178,595) in a Series A backed by Wasteland Investments, Barco Limpo and NLC. Recorded total funding is $2,371,720. The 2024 round and the subsequent public focus on hearing diagnostics indicate continued effort to advance medical applications, particularly objective testing through brain-response analysis. Product listings span hearing, combined hearing-and-vision screening, visual acuity and BCI-enabled communication, suggesting development across related use cases rather than a single diagnostic product. However, the available milestones do not establish sales, clinical adoption, product-launch dates or financing after 2024. The company is marked active, has an employee range of one to ten, and states that it is not currently hiring. These signals support a cautious view: technical and product development is evident, while the pace and commercial scale of growth remain unclear.